Profil
Rob Ortmann worked as an Executive Director of Clinical Development at Horizon Therapeutics Plc from 2021 to 2022.
Prior to that, he worked as the Head of US Immunology at AstraZeneca PLC.
He holds a doctorate degree from Case Western Reserve University School of Medicine.
Ehemalige bekannte Positionen von Rob Ortmann
Unternehmen | Position | Ende |
---|---|---|
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Technik-/Wissenschafts-/F&E-Leiter | 01.05.2022 |
ASTRAZENECA PLC | Corporate Officer/Principal | - |
Ausbildung von Rob Ortmann
Case Western Reserve University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ASTRAZENECA PLC | Health Technology |
Private Unternehmen | 1 |
---|---|
Horizon Therapeutics Plc
Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |